Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy

Myrto Kostopoulou; Antonis Fanouriakis; George Bertsias; Dimitrios T Boumpas

doi:10.1136/ard-2023-223880

Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy

Ann Rheum Dis. 2023 Jun;82(6):729-733. doi: 10.1136/ard-2023-223880. Epub 2023 Apr 24.

Authors

Myrto Kostopoulou¹, Antonis Fanouriakis^{1

2}, George Bertsias^{3

4}, Dimitrios T Boumpas^{5

6}

Affiliations

¹ Rheumatology and Clinical Immunology, National and Kapodistrian University, Athens, Greece.
² First Department of Propaedeutic Internal Medicine, National and Kapodistrian University, Athens, Greece.
³ Rheumatology, University of Crete School of Medicine, Iraklio, Greece.
⁴ Laboratory of Autoimmunity-Inflammation, Institute of Molecular Biology and Biotechnology, Heraklion, Greece.
⁵ Rheumatology and Clinical Immunology, National and Kapodistrian University, Athens, Greece boumpasd@uoc.gr.
⁶ Laboratory of Autoimmunity and Inflammation, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

PMID: 37094880
DOI: 10.1136/ard-2023-223880

Abstract

No single organ has received as much attention in systemic lupus erythematosus (SLE) as the kidneys. During the period 2019-2022, the Annals of the Rheumatic Diseases published several original papers, brief reports and letters that further elucidate the pathogenesis and advance the management of LN. A selection of representative original papers is highlighted in this review.

Keywords: Autoimmunity; Lupus Erythematosus, Systemic; Lupus Nephritis.

Publication types

Review

MeSH terms

Humans
Lupus Erythematosus, Systemic* / drug therapy
Lupus Nephritis* / drug therapy
Lupus Nephritis* / pathology
Rheumatic Diseases* / therapy